• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Private equity and med-tech M&A: Where there’s smoke there’s barbarians?

Private equity and med-tech M&A: Where there’s smoke there’s barbarians?

July 26, 2011 By Brian Johnson

Last week, the world’s largest private-equity company quietly put its money on the table in what could turn out to be a very big gambling chip in the world of medical device mergers & acquisitions.

In a quarterly earnings announcement, The Blackstone Group (NYSE:BX) confirmed a startlingly large $16.1 billion leveraged-buyout fund, which is about 10 percent of the $159 billion total assets the firm has under management.

While the New York City, N.Y.-based company has primarily been putting cash into real estate deals and is eying the energy markets in the U.S., Blackstone has a history of making some big bets in medical technology. In 2006, Blackstone paid $11 billion to acquire Biomet, Inc. and in 2007 it bankrolled a $1.6 billion buyout of DJO Inc.

And that interest doesn’t seem to be fading. Blackstone, along with several other high profile private-equity firms, has been kicking the tires on several deals in the medical device space, culminating in the recent $6 billion buyout of Kinetic Concepts by Apax and a consortium of Canadian pension funds.

In addition to that deal, there’s some more evidence that medical device companies are looking like attractive leveraged-buyout candidates.

  • In the $21.3 billion Synthes/Johnson & Johnson deal, a consortium of three private equity firms came in second to the New Brunswick, NJ-based healthcare conglomerate, offering a boat-load of cash, and forcing JNJ to up its own bid by about 7 percent.
  • Recently, SeraCare Life Sciences Inc. (NSDQ:SRLS) said in regulatory filings that it was poised for a $82 million buyout by private equity firm MSMB Capital.

Does all this activity portend a mega-deal is in the works in med-tech? Perhaps not. However, if private-equity firms are looking to dig their heels into a whale of a deal like JNJ/Synthes, then that means that there’s likely as much smoke as there is fire in a hot season for M&A.

For now, the large medical device companies still have the inside track on acquiring most companies. However, even the Medtronics of the world face restrictions on how much cash they can spend on deals to boost their bottom line, despite the fact that most have been sitting on oodles of cash for years now.

And there’s also a perception gap; regulatory filings showed that Synthes ultimately went with JNJ’s offer because they couldn’t believe that private equity companies could come up with the kind of cash needed to make a $20 billion plus deal.

However, new evidence shows that this may not be the case.

A new EnY report showed that PE firms brought more than 84 companies public through IPOs over the last three months and as of the end of the second quarter there were 88 PE-backed companies registered to go public, which could raise more than $20 billion across global exchanges.

PE firms don’t seem to be as constrained by the credit crunch in the U.S., evidenced by Blackstone’s president Tony James, who told analysts on their earnings call that unlike most industries in America, “the banks have been very accommodating of credit to private equity.”

Flush with cash and with access to credit, the re-arrival of private-equity could be very good news for small companies looking to increase their valuation. However, it’s also bad news for the big med-tech players, which have enjoyed an unprecedented period of bargain hunting since the recession hit in 2008 and don’t want anyone driving up the prices on the market. After all, would you want to call the bluff of a player with $16 billion in chips?

Then again, if private-equity is for real than perhaps those big companies might find themselves with an offer they can’t refuse, or an ante they can’t match.

And, that’s when the fun really starts.

Filed Under: Business/Financial News, Mergers & Acquisitions, News Well Tagged With: depuysynthes, Johnson and Johnson, Kinetic Concepts Inc., MSMB Capital, SeraCare Life Sciences Inc., The Blackstone Group LP

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy